# IDP-023

Source: https://onco.cc/drugs/idp-023/  
OnCo record `idp-023` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IDP-023 is an experimental allogeneic natural killer cell therapy from Indapta Therapeutics, in phase 2 trials for relapsed or refractory multiple myeloma and relapsed or refractory non-Hodgkin lymphoma.

## Summary

IDP-023 (g-NK cells) is an allogeneic natural killer (NK) cell therapy from Indapta Therapeutics. Off-the-shelf NK cells from healthy donors, drawn from a subset deficient in the FceR1g protein (g-NK cells); given alone or with tumour-targeting antibodies. Its furthest stage is phase 2, for relapsed or refractory multiple myeloma and relapsed or refractory non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. NCT06119685 (phase 1/2, haematologic cancers) RECRUITING. The multiple sclerosis study NCT06677710 is SUSPENDED (non-oncology). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: g-NK cells
- Tags: pipeline; ctgov-ingest
- Code: IDP-023
- Modality: Allogeneic natural killer (NK) cell therapy
- Mechanism: Off-the-shelf NK cells from healthy donors, drawn from a subset deficient in the FceR1g protein (g-NK cells); given alone or with tumour-targeting antibodies.

## Sources

- Indapta Therapeutics: indapta.com: https://indapta.com/
- Indapta Therapeutics: indapta.com: https://indapta.com/
- Indapta Therapeutics: indapta.com: https://indapta.com/
- Indapta Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06119685
- ClinicalTrials.gov: trials of IDP-023: https://clinicaltrials.gov/search?intr=IDP-023

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- companies: [Indapta Therapeutics](https://onco.cc/companies/indapta-therapeutics/)
- trials: [IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers](https://onco.cc/trials/nct06119685/)

---
JSON: https://onco.cc/api/v1/entities/idp-023.json